Eagle Pharmaceuticals (Eagle Pharmaceuticals) Change In Receivables : $-29.2 Mil (TTM As of Jun. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Eagle Pharmaceuticals Change In Receivables?

Eagle Pharmaceuticals's change in receivables for the quarter that ended in Jun. 2023 was $-0.2 Mil. It means Eagle Pharmaceuticals's Accounts Receivable increased by $0.2 Mil from Mar. 2023 to Jun. 2023 .

Eagle Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2022 was $-30.8 Mil. It means Eagle Pharmaceuticals's Accounts Receivable increased by $30.8 Mil from Dec. 2021 to Dec. 2022 .

Eagle Pharmaceuticals's Accounts Receivable for the quarter that ended in Jun. 2023 was $115.1 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Eagle Pharmaceuticals's Days Sales Outstanding for the three months ended in Jun. 2023 was 162.52.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Eagle Pharmaceuticals's liquidation value for the three months ended in Jun. 2023 was $-29.8 Mil.

Eagle Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Eagle Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eagle Pharmaceuticals Change In Receivables Chart

Eagle Pharmaceuticals Annual Data

Trend

Sep13

Sep14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

-12.67

18.48

-3.11

9.53

-30.83

Eagle Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Change In Receivables	Get a 7-Day Free Trial															45.40	-11.01	24.49	-42.52	-0.19

Eagle Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.2 Mil.

Eagle Pharmaceuticals (NAS:EGRX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Eagle Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	115.14	/	64.646	*	91
=	162.52

2. In Ben Graham's calculation of liquidation value, Eagle Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Eagle Pharmaceuticals's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	15.354	-	152.782	+	0.75 * 115.14	+	0.5 * 42.482
=	-29.8

Eagle Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Eagle Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Eagle Pharmaceuticals (Eagle Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eagle Pharmaceuticals Inc (NAS:EGRX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

1E6:Germany

Address

50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677

Website

http://www.eagleus.com

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.

Executives

Scott Tarriff	director, officer: President and CEO	28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Richard A. Edlin	director	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Michael Shawn Moran	officer: EVP, Chief Commercial Officer	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF NJ 07677
Luciana Borio	director	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Brian Joseph Cahill	officer: Chief Financial Officer	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Judith Ng-cashin	officer: Chief Medical Officer	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Hudson Executive Capital Lp	director	C/O CADWALADER, WICKERSHAM & TAFT, LLP, 200 LIBERTY STREET, NEW YORK NY 10281
Hec Management Gp Llc	director	1185 AVENUE OF THE AMERICAS, 32ND FLOOR, NEW YORK NY 10036
Jennifer K. Simpson	director	C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Douglas L Braunstein	director	HUDSON EXECUTIVE CAPITAL LP, 570 LEXINGTON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Sander A Flaum	director	630 PARK AVE, NEW YORK NY 10019
Pete A. Meyers	officer: Chief Financial Officer	C/O TETRALOGIC PHARMACEUTICALS CORP, 343 PHOENIXVILLE PIKE, MALVERN PA 19355
David Pernock	director	405 EAGLEVIEW BOULEVARD, EXTON PA 19341
Proquest Investments Iv, L.p.	10 percent owner	2430 VANDERBILT BEACH ROAD, #108 - 190, NAPLES FL 34109
Steven L. Krill	officer: Chief Scientific Officer	C/O EAGLE PHARMCEUTICALS, INC., 50 TICE BLVD. SUITE 315, WOODCLIFF LAKE NJ 07677